Matthew Roden

Matthew Roden is from Princeton, New Jersey, United States. Matthew is currently Board of Directors at Biotech in stealth. Matthew also works as Board of Directors at Orna Therapeutics, a job Matthew has held since May 2024. Another title Matthew currently holds is President and Chief Executive Officer, and member of the Board of Directors at Aktis Oncology. In Matthew's previous role as a Board of Directors at NextPoint Therapeutics, Inc., Matthew worked in until Dec 2024. Prior to joining NextPoint Therapeutics, Inc., Matthew was a Board of Directors at ReNAgade Therapeutics and held the position of Board of Directors. Prior to that, Matthew was a Board of Directors at iTeos Therapeutics from Dec 2020 to Jan 2023. Matthew started working as Chairman of the Board at Turmeric Acquisition Corporation in Sep 2020. From Nov 2019 to Aug 2020, Matthew was Senior Vice President, Head of Enterprise Strategy at Bristol-Myers Squibb. Prior to that, Matthew was a Board of Trustees at BioNJ from Jan 2016 to Jan 2020. Matthew started working as Head of Strategic Corporate Development, and Global BD Assessment at Bristol-Myers Squibb in Princeton, NJ in Jan 2016.